Madrigal Pharmaceuticals (MDGL) PT Raised to $375 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $431.70 --0%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 25 | New: 0
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 25 | New: 0
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $375.00 (from $320.00) while maintaining a Outperform rating.
You May Also Be Interested In
- B.Riley Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
- SanDisk (SNDK) PT Lowered to $2,000 at Goldman Sachs
- CareDx, Inc (CDNA) PT Raised to $92 at BTIG
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
